Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

ULYM18040 / DLBCL / Carla Casulo

Research Question:
What is the correlation between an adapted PET scan and residual cancer cells, as measured by circulating tumor DNA in patients with early stage diffuse large B cell lymphoma?

Basic Study Information

Purpose:
The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.

Location: University of Rochester Medical Center
Study Reference #: ULYM18040

Lead Researcher (Principal Investigator)

Lead Researcher:  Carla Casulo

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search